ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting • Phase III • Oncology • NCT06973187.
- What is being tested: BGB-16673, a novel BTK inhibitor, is being evaluated against pirtobrutinib (an established BTK inhibitor) in patients with relapsed/refractory CLL or SLL who have received prior treatment.
- Patient eligibility overview: Adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have undergone previous treatment regimens are eligible for this comparative efficacy and safety study.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Eligibility Snapshot
- : * Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria * Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi. * Participants with SLL must have measurable disease by computed tomography/magnetic resonance imaging, defined as ≥ 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular diameters.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.